Clinical outcomes of SARS-CoV-2 infection in kidney transplant recipients on belatacept: a single-center experience
Transpl Infect Dis
.
2024 Apr;26(2):e14253.
doi: 10.1111/tid.14253.
Epub 2024 Feb 13.
Authors
Fionna Feller
1
2
,
Marwan M Azar
3
,
Jennifer Marvin
4
,
Elizabeth Cohen
4
,
Sarthak Virmani
5
,
Maricar Malinis
3
Affiliations
1
Division of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
2
Section of Infectious Diseases, Veteran Affairs Tennessee Valley Healthcare, Nashville, Tennessee, USA.
3
Section of Infectious Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.
4
Department of Pharmacy, Yale New Haven Hospital, New Haven, Connecticut, USA.
5
Division of Nephrology, University of Virginia Health, Charlottesville, Virginia, USA.
PMID:
38351494
DOI:
10.1111/tid.14253
No abstract available
Publication types
Letter
MeSH terms
Abatacept / therapeutic use
COVID-19*
Humans
Immunosuppressive Agents / adverse effects
Kidney Transplantation* / adverse effects
SARS-CoV-2
Transplant Recipients
Substances
Abatacept
Immunosuppressive Agents